Presentation Title

Repurposing FDA-approved drugs as combination therapies against Bacillus pathogens

Faculty Mentor

Mikhail Martchenko, Anastasia Levitin

Start Date

23-11-2019 10:45 AM

End Date

23-11-2019 11:30 AM

Location

108

Session

poster 4

Type of Presentation

Poster

Subject Area

biological_agricultural_sciences

Abstract

As pathogens mutate to overcome their respective therapies, current treatments for bacterial infections are proving to be insufficient against the growing influx of multidrug-resistant bacteria. The process to develop novel agents, however, is arduous; this pathway to market can be mitigated by repurposing pre-existing drugs. To accomplish this, 18 FDA-approved drugs were screened in combination against the wild type and yetL mutant of Bacillus subtilis, as surrogates for B. anthracis. Here we report an antiparasitic and an antifungal that together demonstrated an inhibitory effect on both strains of B. subtilis. This combination was screened on four additional bacterial strains and confirmed to have broad-spectrum antibacterial properties. Future studies will evaluate the nature of these two drugs and their resulting combination therapy against cutaneous B. anthracis toxins in animal models.

Keywords: Drug repurposing, drug discovery, drug combinations, infectious diseases, anthrax, Bacillus

This document is currently not available here.

Share

COinS
 
Nov 23rd, 10:45 AM Nov 23rd, 11:30 AM

Repurposing FDA-approved drugs as combination therapies against Bacillus pathogens

108

As pathogens mutate to overcome their respective therapies, current treatments for bacterial infections are proving to be insufficient against the growing influx of multidrug-resistant bacteria. The process to develop novel agents, however, is arduous; this pathway to market can be mitigated by repurposing pre-existing drugs. To accomplish this, 18 FDA-approved drugs were screened in combination against the wild type and yetL mutant of Bacillus subtilis, as surrogates for B. anthracis. Here we report an antiparasitic and an antifungal that together demonstrated an inhibitory effect on both strains of B. subtilis. This combination was screened on four additional bacterial strains and confirmed to have broad-spectrum antibacterial properties. Future studies will evaluate the nature of these two drugs and their resulting combination therapy against cutaneous B. anthracis toxins in animal models.

Keywords: Drug repurposing, drug discovery, drug combinations, infectious diseases, anthrax, Bacillus